Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States

By rosaguerrero • May 9, 2022

Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A, Gaglani M, McNeal T, Ghamande S, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning DJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, Ten Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C, Gershengorn HB, Babcock HM, Kwon JH, Halasa N, Chappell JD, Lauring AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart KW, Zhu Y, Olson SM, Stephenson M, Schrag SJ, Kobayashi M, Verani JR, Self WH; Influenza and Other Viruses in the Acutely Ill (IVY) Network. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin Infect Dis. 2022 May 3;74(9):1515-1524. doi: 10.1093/cid/ciab687. PMID: 34358310; PMCID: PMC8436392.

Tags: covid-19, immunocompromised, mRNA vaccines, Publications, Pulmonary, Critical Care & Sleep Medicine, vaccine effectiveness

Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis

Kellner DA, Dente E, Tran V, Welsh T, Tran V, Saha A, Baker JF, Elashoff DA, Ranganath VK. Effect of Glucagon-Like Peptide 1 Receptor Agonists[...]

Demographics and Trends of Sudden Cardiac Death-Related Mortality in the United States, 1999 to 2022

Jaiswal V, Kumar D, Mashkoor Y, Latif F, Kanagala SG, Halder A, Jaiswal A, Bandyopadhyay D, Hajra A, Joshi A, Aronow WS, Fonarow GC. Demographics[...]

Machine Learning to Diagnose Complications of Diabetes

Scheideman AF, Shao MM, Zelada H, Cuadros J, Foreman J, Sarder P, Ho C, Ejskjaer N, Fleischer J, Cichosz SL, Armstrong DG, Mathioudakis N, Wang[...]